O	0	11	Conclusions	Conclusion	NNS	B-NP

O	12	16	Only	Only	RB	B-ADVP
O	17	22	after	after	IN	B-PP
O	23	30	careful	careful	JJ	B-NP
O	31	44	consideration	consideration	NN	I-NP
O	45	47	of	of	IN	B-PP
O	48	51	the	the	DT	B-NP
O	52	62	biological	biological	JJ	I-NP
O	63	76	underpinnings	underpinning	NNS	I-NP
O	77	79	of	of	IN	B-PP
O	80	81	a	a	DT	B-NP
O	82	87	truly	truly	RB	I-NP
O	88	98	beneficial	beneficial	JJ	I-NP
O	99	107	response	response	NN	I-NP
O	108	111	can	can	MD	O
O	112	114	an	an	DT	B-NP
O	115	123	exposure	exposure	NN	I-NP
O	124	126	be	be	VB	B-VP
O	127	137	considered	consider	VBN	I-VP
O	138	141	for	for	IN	B-PP
O	142	145	the	the	DT	B-NP
O	146	153	general	general	JJ	I-NP
O	154	164	population	population	NN	I-NP
O	164	165	,	,	,	O
O	166	170	such	such	JJ	B-PP
O	171	173	as	as	IN	I-PP
O	174	177	the	the	DT	B-NP
O	178	186	addition	addition	NN	I-NP
O	187	189	of	of	IN	B-PP
O	190	195	folic	folic	JJ	B-NP
O	196	200	acid	acid	NN	I-NP
O	201	203	to	to	TO	B-PP
O	204	211	cereals	cereal	NNS	B-NP
O	211	212	.	.	.	O

O	213	215	If	If	IN	B-SBAR
O	216	217	a	a	DT	B-NP
O	218	223	toxic	toxic	JJ	I-NP
O	224	226	or	or	CC	I-NP
O	227	236	hazardous	hazardous	JJ	I-NP
O	237	246	pollutant	pollutant	NN	I-NP
O	247	251	were	be	VBD	B-VP
O	252	257	found	find	VBN	I-VP
O	258	260	to	to	TO	I-VP
O	261	265	have	have	VB	I-VP
O	266	271	truly	truly	RB	B-NP
O	272	282	beneficial	beneficial	JJ	I-NP
O	283	290	effects	effect	NNS	I-NP
O	291	293	at	at	IN	B-PP
O	294	297	low	low	JJ	B-NP
O	298	302	dose	dose	NN	I-NP
O	302	303	,	,	,	O
O	304	308	then	then	RB	B-ADVP
O	309	313	that	that	IN	B-SBAR
O	314	319	agent	agent	NN	B-NP
O	320	326	should	should	MD	B-VP
O	327	329	be	be	VB	I-VP
O	330	336	tested	test	VBN	I-VP
O	337	347	clinically	clinically	RB	B-ADVP
O	347	348	,	,	,	O
O	349	351	go	go	VB	B-VP
O	352	359	through	through	IN	B-PP
O	360	363	the	the	DT	B-NP
O	364	365	U	U	NNP	I-NP
O	365	366	.	.	.	I-NP
O	366	367	S	S	NNP	I-NP
O	367	368	.	.	.	O

O	369	373	Food	Food	NNP	B-NP
O	374	377	and	and	CC	I-NP
O	378	382	Drug	Drug	NNP	I-NP
O	383	397	Administration	Administration	NNP	I-NP
O	398	399	(	(	(	O
O	399	402	FDA	FDA	NNP	O
O	402	403	)	)	)	O
O	404	412	approval	approval	NN	B-NP
O	413	420	process	process	NN	I-NP
O	420	421	,	,	,	O
O	422	425	and	and	CC	O
O	426	428	be	be	VB	B-VP
O	429	438	regulated	regulate	VBN	I-VP
O	439	441	as	as	IN	B-PP
O	442	443	a	a	DT	B-NP
O	444	458	pharmaceutical	pharmaceutical	JJ	I-NP
O	459	462	for	for	IN	B-PP
O	463	468	those	those	DT	B-NP
O	469	472	who	who	WP	B-NP
O	473	478	might	might	MD	B-VP
O	479	486	benefit	benefit	VB	I-VP
O	487	491	from	from	IN	B-PP
O	492	495	its	its	PRP$	B-NP
O	496	499	use	use	NN	I-NP
O	499	500	.	.	.	O

O	501	510	Certainly	Certainly	RB	B-ADVP
O	510	511	,	,	,	O
O	512	515	the	the	DT	B-NP
O	516	523	general	general	JJ	I-NP
O	524	534	population	population	NN	I-NP
O	535	541	should	should	MD	B-VP
O	542	545	not	not	RB	I-VP
O	546	548	be	be	VB	I-VP
O	549	556	exposed	expose	VBN	I-VP
O	557	559	to	to	TO	B-PP
O	560	576	chemotherapeutic	chemotherapeutic	JJ	B-NP
O	577	583	agents	agent	NNS	I-NP
O	584	588	that	that	WDT	B-NP
O	589	596	benefit	benefit	VBP	B-VP
B-Cancer	597	603	cancer	cancer	NN	B-NP
O	604	612	patients	patient	NNS	I-NP
O	612	613	.	.	.	O

O	614	617	For	For	IN	B-PP
O	618	633	pharmaceuticals	pharmaceutical	NNS	B-NP
O	633	634	,	,	,	O
O	635	637	it	it	PRP	B-NP
O	638	640	is	be	VBZ	B-VP
O	641	651	understood	understand	VBN	I-VP
O	652	656	that	that	IN	B-SBAR
O	657	662	there	there	EX	B-NP
O	663	666	are	be	VBP	B-VP
O	667	672	trade	trade	NN	B-NP
O	673	677	offs	off	NNS	I-NP
O	678	685	between	between	IN	B-PP
O	686	694	benefits	benefit	NNS	B-NP
O	695	698	and	and	CC	I-NP
O	699	704	risks	risk	NNS	I-NP
O	704	705	.	.	.	O

O	706	709	For	For	IN	B-PP
O	710	717	example	example	NN	B-NP
O	717	718	,	,	,	O
O	719	727	although	although	IN	B-SBAR
O	728	735	aspirin	aspirin	NN	B-NP
O	736	738	is	be	VBZ	B-VP
O	739	740	a	a	DT	O
O	741	750	generally	generally	RB	B-ADVP
O	751	755	well	well	RB	I-ADVP
O	755	756	-	-	HYPH	B-NP
O	756	765	tolerated	tolerate	VBN	I-NP
O	766	770	pain	pain	NN	I-NP
O	771	779	reliever	reliever	NN	I-NP
O	780	783	and	and	CC	O
O	784	786	is	be	VBZ	B-VP
O	787	799	increasingly	increasingly	RB	I-VP
O	800	809	advocated	advocate	VBN	I-VP
O	810	812	as	as	IN	B-PP
O	813	814	a	a	DT	B-NP
O	815	827	preventative	preventative	JJ	I-NP
O	828	832	tool	tool	NN	I-NP
O	833	836	for	for	IN	B-PP
B-Organ	837	842	heart	heart	NN	B-NP
O	843	850	attacks	attack	NNS	I-NP
O	851	854	and	and	CC	O
B-Cancer	855	865	colorectal	colorectal	JJ	B-NP
I-Cancer	866	872	cancer	cancer	NN	I-NP
O	873	874	(	(	(	O
O	874	880	Vainio	Vainio	NNP	B-NP
O	881	884	and	and	CC	O
O	885	891	Miller	Miller	NNP	B-NP
O	892	896	2003	2003	CD	I-NP
O	896	897	;	;	:	O
O	898	904	Werner	Werner	NNP	B-NP
O	905	907	et	et	FW	I-NP
O	908	910	al	al	FW	I-NP
O	910	911	.	.	.	I-NP
O	912	916	2004	2004	CD	I-NP
O	916	917	)	)	)	O
O	917	918	,	,	,	O
O	919	921	it	it	PRP	B-NP
O	922	924	is	be	VBZ	B-VP
O	925	929	also	also	RB	I-VP
O	930	936	linked	link	VBN	I-VP
O	937	939	to	to	TO	B-PP
O	940	949	increased	increase	VBN	B-NP
O	950	954	risk	risk	NN	I-NP
O	955	957	of	of	IN	B-PP
B-Organism_subdivision	958	974	gastrointestinal	gastrointestinal	JJ	B-NP
O	975	983	bleeding	bleeding	NN	I-NP
O	983	984	,	,	,	O
B-Organ	985	993	cerebral	cerebral	JJ	B-NP
O	994	1004	hemorrhage	hemorrhage	NN	I-NP
O	1005	1006	(	(	(	O
O	1006	1012	Werner	Werner	NNP	B-NP
O	1013	1015	et	et	FW	I-NP
O	1016	1018	al	al	FW	I-NP
O	1018	1019	.	.	.	I-NP
O	1020	1024	2004	2004	CD	I-NP
O	1024	1025	)	)	)	O
O	1025	1026	,	,	,	O
O	1027	1030	and	and	CC	O
O	1031	1037	asthma	asthma	NN	B-NP
O	1038	1045	attacks	attack	NNS	I-NP
O	1046	1047	(	(	(	O
O	1047	1054	Jenkins	Jenkins	NNP	B-NP
O	1055	1057	et	et	FW	I-NP
O	1058	1060	al	al	FW	I-NP
O	1060	1061	.	.	.	I-NP
O	1062	1066	2004	2004	CD	I-NP
O	1066	1067	)	)	)	O
O	1067	1068	.	.	.	O

O	1069	1071	In	In	IN	B-PP
O	1072	1080	addition	addition	NN	B-NP
O	1080	1081	,	,	,	O
O	1082	1089	aspirin	aspirin	NN	B-NP
O	1090	1092	is	be	VBZ	B-VP
O	1093	1096	not	not	RB	I-VP
O	1097	1108	recommended	recommend	VBN	I-VP
O	1109	1112	for	for	IN	B-PP
O	1113	1121	children	child	NNS	B-NP
O	1122	1124	or	or	CC	I-NP
O	1125	1134	teenagers	teenager	NNS	I-NP
O	1135	1138	who	who	WP	B-NP
O	1139	1143	have	have	VBP	B-VP
O	1144	1146	or	or	CC	O
O	1147	1150	are	be	VBP	B-VP
O	1151	1161	recovering	recover	VBG	I-VP
O	1162	1166	from	from	IN	B-PP
O	1167	1174	chicken	chicken	NN	B-NP
O	1175	1178	pox	pox	NN	I-NP
O	1179	1181	or	or	CC	O
O	1182	1189	flulike	flulike	JJ	B-NP
O	1190	1198	symptoms	symptom	NNS	I-NP
O	1199	1206	because	because	IN	B-SBAR
O	1207	1209	it	it	PRP	B-NP
O	1210	1213	can	can	MD	B-VP
O	1214	1219	cause	cause	VB	I-VP
O	1220	1232	debilitating	debilitate	VBG	I-VP
O	1233	1236	and	and	CC	O
O	1237	1246	sometimes	sometimes	RB	B-NP
O	1247	1253	lethal	lethal	JJ	I-NP
O	1254	1259	Reyes	Reyes	NNP	I-NP
O	1260	1268	syndrome	syndrome	NN	I-NP
O	1269	1270	(	(	(	O
O	1270	1271	U	U	NNP	B-NP
O	1271	1272	.	.	.	I-NP
O	1272	1273	S	S	NNP	I-NP
O	1273	1274	.	.	.	I-NP
O	1275	1278	FDA	FDA	NNP	I-NP
O	1279	1283	2003	2003	CD	I-NP
O	1283	1284	)	)	)	O
O	1284	1285	.	.	.	O

O	1286	1296	Individual	Individual	JJ	B-NP
O	1297	1302	risks	risk	NNS	I-NP
O	1303	1305	to	to	TO	B-PP
O	1306	1320	pharmaceutical	pharmaceutical	JJ	B-NP
O	1321	1327	agents	agent	NNS	I-NP
O	1328	1331	can	can	MD	B-VP
O	1332	1334	be	be	VB	I-VP
O	1335	1345	controlled	control	VBN	I-VP
O	1346	1350	with	with	IN	B-PP
O	1351	1357	proper	proper	JJ	B-NP
O	1358	1363	usage	usage	NN	I-NP
O	1363	1364	;	;	:	O
O	1365	1372	however	however	RB	B-ADVP
O	1372	1373	,	,	,	O
O	1374	1383	increased	increase	VBN	B-NP
O	1384	1392	exposure	exposure	NN	I-NP
O	1393	1395	to	to	TO	B-PP
O	1396	1409	environmental	environmental	JJ	B-NP
O	1410	1416	toxins	toxin	NNS	I-NP
O	1417	1425	presents	present	VBZ	B-VP
O	1426	1436	additional	additional	JJ	B-NP
O	1437	1448	involuntary	involuntary	JJ	I-NP
O	1449	1454	risks	risk	NNS	I-NP
O	1455	1458	for	for	IN	B-PP
O	1459	1462	the	the	DT	B-NP
O	1463	1470	general	general	JJ	I-NP
O	1471	1481	population	population	NN	I-NP
O	1481	1482	.	.	.	O

O	1483	1488	Under	Under	IN	B-PP
O	1489	1492	the	the	DT	B-NP
O	1493	1499	latter	latter	JJ	I-NP
O	1500	1509	condition	condition	NN	I-NP
O	1509	1510	,	,	,	O
O	1511	1519	exposure	exposure	NN	B-NP
O	1520	1522	is	be	VBZ	B-VP
O	1523	1535	inadequately	inadequately	RB	I-VP
O	1536	1546	controlled	control	VBN	I-VP
O	1546	1547	,	,	,	O
O	1548	1551	and	and	CC	O
O	1552	1557	there	there	EX	B-NP
O	1558	1560	is	be	VBZ	B-VP
O	1561	1563	no	no	DT	B-NP
O	1564	1573	mechanism	mechanism	NN	I-NP
O	1574	1576	to	to	TO	B-VP
O	1577	1584	correct	correct	VB	I-VP
O	1585	1588	for	for	IN	B-PP
O	1589	1599	individual	individual	JJ	B-NP
O	1600	1613	circumstances	circumstance	NNS	I-NP
O	1614	1615	(	(	(	O
O	1615	1616	e	e	JJ	B-NP
O	1616	1617	.	.	.	I-NP
O	1617	1618	g	g	NN	I-NP
O	1618	1619	.	.	.	O
O	1619	1620	,	,	,	O
O	1621	1628	medical	medical	JJ	B-NP
O	1629	1638	condition	condition	NN	I-NP
O	1639	1641	or	or	CC	O
O	1642	1645	age	age	NN	B-NP
O	1645	1646	)	)	)	O
O	1647	1651	that	that	WDT	B-NP
O	1652	1655	may	may	MD	B-VP
O	1656	1662	result	result	VB	I-VP
O	1663	1665	in	in	IN	B-PP
O	1666	1670	harm	harm	NN	B-NP
O	1670	1671	.	.	.	O

O	1672	1680	Although	Although	IN	B-SBAR
O	1681	1689	hormetic	hormetic	JJ	B-NP
O	1690	1697	effects	effect	NNS	I-NP
O	1698	1701	may	may	MD	B-VP
O	1702	1707	occur	occur	VB	I-VP
O	1708	1710	in	in	IN	B-PP
O	1711	1715	some	some	DT	B-NP
O	1716	1725	instances	instance	NNS	I-NP
O	1725	1726	,	,	,	O
O	1727	1729	it	it	PRP	B-NP
O	1730	1732	is	be	VBZ	B-VP
O	1733	1739	indeed	indeed	RB	B-ADJP
O	1740	1744	rare	rare	JJ	I-ADJP
O	1745	1749	that	that	IN	B-SBAR
O	1750	1759	exposures	exposure	NNS	B-NP
O	1760	1762	to	to	TO	B-PP
O	1763	1768	toxic	toxic	JJ	B-NP
O	1768	1769	,	,	,	I-NP
O	1770	1779	mutagenic	mutagenic	JJ	I-NP
O	1779	1780	,	,	,	I-NP
O	1781	1792	teratogenic	teratogenic	JJ	I-NP
O	1792	1793	,	,	,	O
O	1794	1797	and	and	CC	O
O	1798	1810	carcinogenic	carcinogenic	JJ	B-NP
O	1811	1820	chemicals	chemical	NNS	I-NP
O	1820	1821	,	,	,	O
O	1822	1826	even	even	RB	B-ADVP
O	1827	1829	at	at	IN	B-PP
O	1830	1833	low	low	JJ	B-NP
O	1834	1842	exposure	exposure	NN	I-NP
O	1843	1849	levels	level	NNS	I-NP
O	1849	1850	,	,	,	O
O	1851	1856	would	would	MD	B-VP
O	1857	1859	be	be	VB	I-VP
O	1860	1864	risk	risk	NN	B-NP
O	1865	1869	free	free	JJ	B-ADJP
O	1870	1873	and	and	CC	O
O	1874	1881	provide	provide	VBP	B-VP
O	1882	1888	health	health	NN	B-NP
O	1889	1897	benefits	benefit	NNS	I-NP
O	1898	1901	for	for	IN	B-PP
O	1902	1905	the	the	DT	B-NP
O	1906	1913	general	general	JJ	I-NP
O	1914	1920	public	public	NN	I-NP
O	1920	1921	.	.	.	O

O	1922	1932	Portraying	Portray	VBG	B-VP
O	1933	1942	chemicals	chemical	NNS	B-NP
O	1943	1947	with	with	IN	B-PP
O	1948	1956	numerous	numerous	JJ	B-NP
O	1957	1964	adverse	adverse	JJ	I-NP
O	1965	1972	effects	effect	NNS	I-NP
O	1973	1975	as	as	IN	B-PP
O	1976	1982	having	have	VBG	B-VP
O	1983	1991	benefits	benefit	NNS	B-NP
O	1992	1997	while	while	IN	B-SBAR
O	1998	2006	ignoring	ignore	VBG	B-VP
O	2007	2012	their	their	PRP$	B-NP
O	2013	2020	hazards	hazard	NNS	I-NP
O	2021	2023	is	be	VBZ	B-VP
O	2024	2037	irresponsible	irresponsible	JJ	B-ADJP
O	2038	2041	and	and	CC	O
O	2042	2046	does	do	VBZ	B-VP
O	2047	2050	not	not	RB	I-VP
O	2051	2058	provide	provide	VB	I-VP
O	2059	2063	full	full	JJ	B-NP
O	2064	2067	and	and	CC	I-NP
O	2068	2077	objective	objective	JJ	I-NP
O	2078	2088	disclosure	disclosure	NN	I-NP
O	2088	2089	.	.	.	O

O	2090	2092	In	In	IN	B-PP
O	2093	2096	the	the	DT	B-NP
O	2097	2102	1950s	1950s	CD	I-NP
O	2103	2110	doctors	doctor	NNS	I-NP
O	2111	2121	prescribed	prescribe	VBD	B-VP
O	2122	2125	DES	DES	NNP	B-NP
O	2126	2128	to	to	TO	B-PP
O	2129	2137	pregnant	pregnant	JJ	B-NP
O	2138	2143	women	woman	NNS	I-NP
O	2144	2146	to	to	TO	B-VP
O	2147	2154	prevent	prevent	VB	I-VP
O	2155	2166	miscarriage	miscarriage	NN	B-NP
O	2167	2170	and	and	CC	O
O	2171	2180	premature	premature	JJ	B-NP
O	2181	2187	births	birth	NNS	I-NP
O	2188	2191	and	and	CC	O
O	2192	2194	to	to	TO	B-VP
O	2195	2202	produce	produce	VB	I-VP
O	2203	2204	"	"	''	O
O	2204	2210	bigger	big	JJR	B-NP
O	2211	2214	and	and	CC	I-NP
O	2215	2223	stronger	strong	JJR	I-NP
O	2224	2230	babies	baby	NNS	I-NP
O	2230	2231	"	"	''	O
O	2232	2236	even	even	RB	B-SBAR
O	2237	2243	though	though	IN	I-SBAR
O	2244	2247	DES	DES	NNP	B-NP
O	2248	2251	had	have	VBD	B-VP
O	2252	2256	been	be	VBN	I-VP
O	2257	2262	shown	show	VBN	I-VP
O	2263	2265	to	to	TO	I-VP
O	2266	2271	cause	cause	VB	I-VP
O	2272	2278	damage	damage	NN	B-NP
O	2279	2281	to	to	TO	B-PP
O	2282	2294	reproductive	reproductive	JJ	B-NP
B-Tissue	2295	2302	tissues	tissue	NNS	I-NP
O	2303	2305	in	in	IN	B-PP
O	2306	2313	animals	animal	NNS	B-NP
O	2314	2315	(	(	(	O
O	2315	2323	Dinusson	Dinusson	NNP	B-NP
O	2324	2326	et	et	FW	I-NP
O	2327	2329	al	al	FW	I-NP
O	2329	2330	.	.	.	B-NP
O	2331	2335	1948	1948	CD	I-NP
O	2335	2336	;	;	:	O
O	2337	2341	Dunn	Dunn	NNP	B-NP
O	2342	2345	and	and	CC	O
O	2346	2351	Green	Green	NNP	B-NP
O	2352	2356	1963	1963	CD	I-NP
O	2356	2357	;	;	:	O
O	2358	2366	Takasugi	Takasugi	NNP	B-NP
O	2367	2370	and	and	CC	I-NP
O	2371	2375	Bern	Bern	NNP	I-NP
O	2376	2380	1964	1964	CD	I-NP
O	2380	2381	)	)	)	O
O	2381	2382	.	.	.	O

O	2383	2388	Human	Human	JJ	B-NP
O	2389	2392	use	use	NN	I-NP
O	2393	2395	of	of	IN	B-PP
O	2396	2399	DES	DES	NNP	B-NP
O	2400	2403	was	be	VBD	B-VP
O	2404	2410	banned	ban	VBN	I-VP
O	2411	2413	in	in	IN	B-PP
O	2414	2417	the	the	DT	B-NP
O	2418	2424	United	United	NNP	I-NP
O	2425	2431	States	State	NNPS	I-NP
O	2432	2434	in	in	IN	B-PP
O	2435	2439	1971	1971	CD	B-NP
O	2440	2445	after	after	IN	B-PP
O	2446	2449	the	the	DT	B-NP
O	2450	2459	discovery	discovery	NN	I-NP
O	2460	2462	of	of	IN	B-PP
O	2463	2467	high	high	JJ	B-NP
O	2468	2473	rates	rate	NNS	I-NP
O	2474	2476	of	of	IN	B-PP
O	2477	2481	rare	rare	JJ	B-NP
O	2481	2482	,	,	,	I-NP
O	2483	2488	clear	clear	JJ	I-NP
O	2488	2489	-	-	HYPH	I-NP
O	2489	2493	cell	cell	NN	I-NP
B-Cancer	2494	2509	adenocarcinomas	adenocarcinoma	NNS	I-NP
O	2510	2512	of	of	IN	B-PP
O	2513	2516	the	the	DT	B-NP
B-Multi-tissue_structure	2517	2523	vagina	vagina	NN	I-NP
O	2524	2527	and	and	CC	I-NP
B-Multi-tissue_structure	2528	2534	cervix	cervix	NN	I-NP
O	2535	2537	in	in	IN	B-PP
O	2538	2541	DES	DES	NNP	B-NP
O	2541	2542	-	-	HYPH	B-NP
O	2542	2549	exposed	expose	VBN	I-NP
O	2550	2559	daughters	daughter	NNS	I-NP
O	2560	2561	(	(	(	O
O	2561	2567	Herbst	Herbst	NNP	B-NP
O	2568	2572	1981	1981	CD	I-NP
O	2572	2573	)	)	)	O
O	2573	2574	,	,	,	O
O	2575	2578	and	and	CC	O
O	2579	2584	later	later	JJ	B-NP
O	2585	2592	studies	study	NNS	I-NP
O	2593	2599	showed	show	VBD	B-VP
O	2600	2608	elevated	elevate	VBN	I-VP
B-Cancer	2609	2615	breast	breast	NN	B-NP
I-Cancer	2616	2622	cancer	cancer	NN	I-NP
O	2623	2627	risk	risk	NN	I-NP
O	2628	2630	in	in	IN	B-PP
O	2631	2636	women	woman	NNS	B-NP
O	2637	2640	who	who	WP	B-NP
O	2641	2645	took	take	VBD	B-VP
O	2646	2649	DES	DES	NNP	B-NP
O	2650	2656	during	during	IN	B-PP
O	2657	2666	pregnancy	pregnancy	NN	B-NP
O	2667	2668	(	(	(	O
O	2668	2673	Titus	Titus	NNP	B-NP
O	2673	2674	-	-	HYPH	I-NP
O	2674	2682	Ernstoff	Ernstoff	NNP	I-NP
O	2683	2685	et	et	FW	I-NP
O	2686	2688	al	al	FW	I-NP
O	2688	2689	.	.	.	I-NP
O	2690	2694	2001	2001	CD	I-NP
O	2694	2695	)	)	)	O
O	2695	2696	.	.	.	O

O	2697	2706	Certainly	Certainly	RB	B-ADVP
O	2706	2707	,	,	,	O
O	2708	2714	health	health	NN	B-NP
O	2715	2721	policy	policy	NN	I-NP
O	2722	2731	decisions	decision	NNS	I-NP
O	2732	2738	should	should	MD	B-VP
O	2739	2741	be	be	VB	I-VP
O	2742	2747	based	base	VBN	I-VP
O	2748	2750	on	on	IN	B-PP
O	2751	2761	scientific	scientific	JJ	B-NP
O	2762	2770	evidence	evidence	NN	I-NP
O	2771	2774	and	and	CC	B-PP
O	2775	2778	not	not	RB	B-PP
O	2779	2781	on	on	IN	I-PP
O	2782	2793	speculation	speculation	NN	B-NP
O	2794	2796	of	of	IN	B-PP
O	2797	2803	health	health	NN	B-NP
O	2804	2812	benefits	benefit	NNS	I-NP
O	2813	2815	in	in	IN	B-PP
O	2816	2821	order	order	NN	B-NP
O	2822	2825	for	for	IN	B-PP
O	2826	2829	the	the	DT	B-NP
O	2830	2837	general	general	JJ	I-NP
O	2838	2848	population	population	NN	I-NP
O	2849	2851	to	to	TO	B-VP
O	2852	2857	avoid	avoid	VB	I-VP
O	2858	2867	repeating	repeat	VBG	I-VP
O	2868	2871	the	the	DT	B-NP
O	2872	2880	mistakes	mistake	NNS	I-NP
O	2881	2883	of	of	IN	B-PP
O	2884	2887	the	the	DT	B-NP
O	2888	2892	past	past	NN	I-NP
O	2893	2900	similar	similar	JJ	B-ADJP
O	2901	2903	to	to	TO	B-PP
O	2904	2908	that	that	DT	B-NP
O	2909	2911	of	of	IN	B-PP
O	2912	2915	the	the	DT	B-NP
O	2916	2919	DES	DES	NNP	I-NP
O	2920	2927	tragedy	tragedy	NN	I-NP
O	2927	2928	.	.	.	O

O	2929	2932	The	The	DT	B-NP
O	2933	2939	claims	claim	NNS	I-NP
O	2940	2943	and	and	CC	I-NP
O	2944	2955	projections	projection	NNS	I-NP
O	2956	2958	of	of	IN	B-PP
O	2959	2965	health	health	NN	B-NP
O	2966	2974	benefits	benefit	NNS	I-NP
O	2975	2979	from	from	IN	B-PP
O	2980	2989	exposures	exposure	NNS	B-NP
O	2990	2992	to	to	TO	B-PP
O	2993	3006	environmental	environmental	JJ	B-NP
O	3007	3016	toxicants	toxicant	NNS	I-NP
O	3017	3020	and	and	CC	I-NP
O	3021	3032	carcinogens	carcinogen	NNS	I-NP
O	3033	3036	are	be	VBP	B-VP
O	3037	3042	based	base	VBN	I-VP
O	3043	3045	on	on	IN	B-PP
O	3046	3054	untested	untested	JJ	B-NP
O	3055	3066	assumptions	assumption	NNS	I-NP
O	3067	3070	and	and	CC	O
O	3071	3080	disregard	disregard	VB	B-VP
O	3081	3089	numerous	numerous	JJ	B-ADJP
O	3090	3094	well	well	RB	B-ADVP
O	3094	3095	-	-	HYPH	O
O	3095	3106	established	establish	VBN	B-NP
O	3107	3117	scientific	scientific	JJ	I-NP
O	3118	3128	principles	principle	NNS	I-NP
O	3129	3133	that	that	WDT	B-NP
O	3134	3142	underpin	underpin	VBP	B-VP
O	3143	3144	a	a	DT	B-NP
O	3145	3151	public	public	JJ	I-NP
O	3152	3158	health	health	NN	I-NP
O	3158	3159	-	-	HYPH	I-NP
O	3159	3169	protective	protective	JJ	I-NP
O	3170	3178	approach	approach	NN	I-NP
O	3179	3181	to	to	TO	B-PP
O	3182	3192	regulating	regulate	VBG	B-VP
O	3193	3201	exposure	exposure	NN	B-NP
O	3202	3204	to	to	TO	B-PP
O	3205	3210	toxic	toxic	JJ	B-NP
O	3211	3221	substances	substance	NNS	I-NP
O	3221	3222	.	.	.	O

O	3223	3225	If	If	IN	B-SBAR
O	3226	3234	hormesis	hormesis	NN	B-NP
O	3235	3239	were	be	VBD	B-VP
O	3240	3244	used	use	VBN	I-VP
O	3245	3247	in	in	IN	B-PP
O	3248	3251	the	the	DT	B-NP
O	3252	3260	decision	decision	NN	I-NP
O	3260	3261	-	-	HYPH	O
O	3261	3267	making	make	VBG	B-VP
O	3268	3275	process	process	NN	B-NP
O	3276	3278	to	to	TO	B-VP
O	3279	3284	allow	allow	VB	I-VP
O	3285	3291	higher	high	JJR	B-NP
O	3292	3301	exposures	exposure	NNS	I-NP
O	3302	3304	to	to	TO	B-PP
O	3305	3310	toxic	toxic	JJ	B-NP
O	3311	3314	and	and	CC	I-NP
O	3315	3327	carcinogenic	carcinogenic	JJ	I-NP
O	3328	3334	agents	agent	NNS	I-NP
O	3334	3335	,	,	,	O
O	3336	3340	this	this	DT	B-NP
O	3341	3346	would	would	MD	B-VP
O	3347	3360	substantially	substantially	RB	I-VP
O	3361	3369	increase	increase	VB	I-VP
O	3370	3376	health	health	NN	B-NP
O	3377	3382	risks	risk	NNS	I-NP
O	3383	3386	for	for	IN	B-PP
O	3387	3391	many	many	JJ	B-NP
O	3391	3392	,	,	,	O
O	3393	3395	if	if	IN	B-SBAR
O	3396	3399	not	not	RB	O
O	3400	3404	most	most	JJS	B-NP
O	3404	3405	,	,	,	O
O	3406	3414	segments	segment	NNS	B-NP
O	3415	3417	of	of	IN	B-PP
O	3418	3421	the	the	DT	B-NP
O	3422	3429	general	general	JJ	I-NP
O	3430	3440	population	population	NN	I-NP
O	3440	3441	.	.	.	O

